Publications by authors named "Helene Castanie"

Claim this Profile
T
TFOX versus FOLFOX in first-line treatment of patients with advanced HER2-negative gastric or gastro-oesophageal junction adenocarcinoma (PRODIGE 51- FFCD-GASTFOX): an open-label, multicentre, randomised, phase 3 trial.
Aziz Zaanan, Olivier Bouché, Christelle de la Fouchardière, Karine Le Malicot, Simon Pernot, Hélène Castanie

Lancet Oncol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial.
Joël Guigay, Anne Aupérin, Jérôme Fayette, Esma Saada-Bouzid, Cédrik Lafond, Hélène Castanie

Lancet Oncol· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Triplet combination of durvalumab, tremelimumab, and paclitaxel in biliary tract carcinomas: Safety run-in results of the randomized IMMUNOBIL PRODIGE 57 phase II trial.
Alice Boilève, Marc Hilmi, Paul Gougis, Romain Cohen, Benoît Rousseau

Eur J Cancer· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Lobular breast cancer metastasis to the colon].
Alain Lortholary, Benoît Humeau, Hélène Castanié, Lemia Zgarni-Guillaumet, Claude El Kouri

Presse Med· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis